Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.
Related Posts
Trump’s Win Shows Limits of Biden’s Industrial Policy
Long-term economic investments in domestic manufacturing were overshadowed by real-time anxiety over rent and grocery prices.
Months Before Ethiopian Crash, Boeing Turned Aside Carrier’s Questions
Ethiopian Airlines appeared to foresee the deadly confusion its pilots would face if flawed software in the Boeing 737 Max failed. Boeing chose not to […]
Weak Jobs Report Raises Chances of a September Interest Rate Cut
The Federal Reserve held rates steady in July but two governors dissented, saying they had concerns about labor market fragility.